How do you pay?

How to pay the least

Cash price

$1,710+ for 30 capsules

Pharmacies pay about this for Caplyta; you’d pay more.

  1. Ask your pharmacy for Caplyta’s cash price, and one or two other pharmacies too.
  2. Caplyta’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Johnson & Johnson Patient Assistance Program. Patients’ income must be equal to or less than 300% of Federal Poverty Level (FPL). Or call 1-833-742-0791.

See if you qualify 

No generic is sold yet.

Compare every option

Question
Brand nameCaplyta
Authorized genericlumateperone
Regular genericlumateperone
What you’d pay
At least$1,710for 30 capsules; pharmacies pay this
Not soldThere isn’t one
Not soldNone sold yet
Same as Caplyta?
The original
–
–

Brand nameThe maker’s card

CAPLYTA withMe Savings Program

Savings card from Johnson & Johnson (Intra-Cellular Therapies)

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Print the card (PDF) 

Or text CAPLYTA to 26789. See the offer on caplyta.com

In the maker’s words

“Pay as little as $0 for 30-, 60-, or 90-day prescriptions…”

From the maker’s offer on caplyta.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Caplyta itself, from the same company, sold without the brand name, and usually for less. For now Caplyta is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

No generic is sold yet. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

CAPLYTA is an atypical antipsychotic indicated for:

  • Treatment of schizophrenia in adults.
  • Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
  • Adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.

Source: the FDA label for Caplyta (Intra-Cellular Therapies, Inc), June 20, 2025. Full label on DailyMed 

Good to know